Physician profile
Corrine E Garner
NPI 1275540825
$1,634.53
in general payments reported to CMS, 2019-2025
15 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $366 · 2021: $92.44 · 2022: $253 · 2023: $97.02 · 2024: $89.66 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.06 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $246.12 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $177.39 | 2019-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $117.09 | 2019-2025 | Trintellix |
| Pfizer INC. | $84.23 | 2020-2021 | |
| Allergan, INC. | $78.64 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.93 | 2020 | |
| Merck Sharp & Dohme LLC | $47.07 | 2019 | |
| Abbott Laboratories | $39.56 | 2024-2025 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $26.19 | 2019 | |
| Becton, Dickinson and Company | $17.71 | 2024 | Bd Onclarity |
| Amgen INC. | $15.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.46 | 2019 | |
| Shire North American Group INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrine Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.